Time to Re-focus onto Cognitive Symptoms in Schizophrenia.
作者信息
Reddy M S, Mythri S V
机构信息
Asha Bipolar Clinic, Asha Hospital, Hyderabad, Telangana, India. E-mail:
出版信息
Indian J Psychol Med. 2016 Mar-Apr;38(2):93-6. doi: 10.4103/0253-7176.178765.
Abstract
摘要
相似文献
1
Time to Re-focus onto Cognitive Symptoms in Schizophrenia.
Indian J Psychol Med. 2016 Mar-Apr;38(2):93-6. doi: 10.4103/0253-7176.178765.
2
Schizophrenia is a cognitive illness: time for a change in focus.
JAMA Psychiatry. 2013 Oct;70(10):1107-12. doi: 10.1001/jamapsychiatry.2013.155.
3
Relationship between cognitive insight and subjective quality of life in outpatients with schizophrenia.
Neuropsychiatr Dis Treat. 2015 Aug 7;11:2041-8. doi: 10.2147/NDT.S90143. eCollection 2015.
4
5
Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism.
Pharmacol Ther. 2010 Dec;128(3):419-32. doi: 10.1016/j.pharmthera.2010.07.004. Epub 2010 Aug 10.
6
Relations of symptoms to cognitive deficits in schizophrenia.
Schizophr Bull. 1993;19(2):215-31. doi: 10.1093/schbul/19.2.215.
7
Improvement in prosocial functioning after a switch to ziprasidone treatment.
CNS Spectr. 2004 May;9(5):357-64. doi: 10.1017/s1092852900009342.
8
Intentionality as a link between the neuropsychology and the symptoms of schizophrenia.
Psychopathology. 2007;40(4):221-8. doi: 10.1159/000101364. Epub 2007 Mar 29.
9
Digit symbol coding and general cognitive ability in schizophrenia: worth another look?
Br J Psychiatry. 2008 Nov;193(5):354-6. doi: 10.1192/bjp.bp.108.049387.
10
A Comparison of Methamphetamine-Induced Psychosis and Schizophrenia: A Review of Positive, Negative, and Cognitive Symptomatology.
Front Psychiatry. 2018 Oct 10;9:491. doi: 10.3389/fpsyt.2018.00491. eCollection 2018.
本文引用的文献
1
Current and emergent treatments for symptoms and neurocognitive impairment in schizophrenia.
Curr Treat Options Psychiatry. 2015 Jun;1(2):107-120. doi: 10.1007/s40501-014-0010-9.
2
Do atypical antipsychotics improve cognition?
Psychiatr Danub. 2014 Nov;26 Suppl 1:285-8.
3
Neural basis for the ability of atypical antipsychotic drugs to improve cognition in schizophrenia.
Front Behav Neurosci. 2013 Oct 16;7:140. doi: 10.3389/fnbeh.2013.00140.
4
Cognitive function in schizophrenia: insights from intelligence research.
Br J Psychiatry. 2013 Sep;203(3):161-2. doi: 10.1192/bjp.bp.112.109553.
5
Schizophrenia is a cognitive illness: time for a change in focus.
JAMA Psychiatry. 2013 Oct;70(10):1107-12. doi: 10.1001/jamapsychiatry.2013.155.
6
Food and Drug Administration commentary on methodological issues in negative symptom trials.
Schizophr Bull. 2011 Mar;37(2):255-6. doi: 10.1093/schbul/sbq162. Epub 2011 Jan 18.
7
The treatment of cognitive impairment in schizophrenia.
Pharmacol Biochem Behav. 2011 Aug;99(2):245-53. doi: 10.1016/j.pbb.2010.11.009. Epub 2010 Nov 27.
8
The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later?
Schizophr Bull. 2011 Nov;37(6):1209-17. doi: 10.1093/schbul/sbq038. Epub 2010 Apr 21.
9
A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia.
Schizophr Bull. 2005 Jan;31(1):5-19. doi: 10.1093/schbul/sbi020. Epub 2005 Feb 16.
Zotero 插件